双联抗血小板治疗患者的缺血性卒中静脉溶栓
基于SITS国际卒中溶栓登记2010至2017年前瞻性数据,对双联抗血小板预处理与无抗血小板预处理的急性缺血性卒中静脉溶栓患者进行倾向性评分匹配,各1043例。两组症状性颅内出血、3个月死亡率、良好功能结局及功能独立均无显著差异。作者认为不应因双联抗血小板预处理史而放弃静脉溶栓。
要点
- 双联抗血小板预处理与无抗血小板预处理患者静脉溶栓后症状性颅内出血率无显著差异。
- 两组3个月死亡率、良好功能结局及功能独立均无显著差异。
- 作者认为不应将双联抗血小板预处理史作为不进行静脉溶栓的理由。
核心结论
- 双联抗血小板预处理患者与无抗血小板预处理患者相比,症状性颅内出血、3个月死亡率和功能结局相似,双联抗血小板预处理史不应作为符合条件患者不进行静脉溶栓的理由。
研究设计与样本
- 分析SITS国际卒中溶栓登记中2010至2017年连续接受静脉溶栓的急性缺血性卒中患者的前瞻性数据,采用倾向性评分匹配比较双联抗血小板预处理组与无抗血小板预处理组。
- 双联抗血小板预处理定义为阿司匹林、氯吡格雷、双嘧达莫及任何其他抗血小板药物之间所有可能的组合。
- 倾向性评分匹配后两组各1043例,所有基线特征均衡。
主要发现
- 症状性颅内出血率按SITS-MOST定义双联抗血小板预处理组2.9% vs 无抗血小板预处理组1.5%(95%CI=-0.03至-0.01)。
- 症状性颅内出血率按ECASS II定义双联抗血小板预处理组5.2% vs 无抗血小板预处理组4.4%(95%CI=-0.03至0.01)。
- 症状性颅内出血率按NINDS定义双联抗血小板预处理组7.7% vs 无抗血小板预处理组6.6%(95%CI=-0.03至0.01)。
- 3个月死亡率双联抗血小板预处理组17.9% vs 无抗血小板预处理组16.6%(95%CI=-0.05至0.02)。
- 3个月良好功能结局(mRS 0-1)双联抗血小板预处理组45.6% vs 无抗血小板预处理组46.0%(95%CI=-0.04至0.05),功能独立(mRS 0-2)双联抗血小板预处理组59.2% vs 无抗血小板预处理组60.7%(95%CI=-0.03至0.06),3个月mRS评分分布双联抗血小板预处理组2(1-4) vs 无抗血小板预处理组2(0-4)(95%CI=-0.29至0.09)。
关键数值与推荐
- 症状性颅内出血按SITS-MOST、ECASS II和NINDS三种定义评估,两组比较采用Bonferroni校正后p>0.017为无显著差异。
- 3个月良好功能结局定义为改良Rankin量表评分0-1分,功能独立定义为改良Rankin量表评分0-2分。
临床怎么用
- 作者认为,双联抗血小板预处理史不应作为符合条件急性缺血性卒中患者不进行静脉溶栓的理由。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed the outcomes of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients on dual antiplatelet therapy prior to stroke onset. METHODS: We analyzed prospectively collected data from the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register on consecutive IVT-treated AIS patients during a 7-year period (2010-2017). In propensity score matched groups of patients with dual antiplatelet pretreatment and no antiplatelet pretreatment, we compared: (1) symptomatic intracerebral hemorrhage (SICH), according to SITS Monitoring Study (MOST), European Cooperative Acute Stroke Study (ECASS) II, and National Institute of Neurological Disorders and Stroke (NINDS) definitions; (2) 3-month mortality; (3) 3-month favorable functional outcome (FFO; modified Rankin Scale [mRS] scores = 0-1); (4) 3-month functional independence (FI; mRS scores = 0-2); and (5) distribution of the 3-month mRS scores. Dual antiplatelet pretreatment was defined as all possible combinations among aspirin, clopidogrel, dipyridamole, and any other antiplatelet. RESULTS: Propensity score matching resulted in 2 groups of 1,043 patients each, balanced for all baseline characteristics. In the propensity score matched analysis, the 2 groups had comparable (p > 0.017 using Bonferroni correction for multiple comparisons) SICH rates according to SITS-MOST (2.9% vs 1.5%, 95% confidence interval [CI] = -0.03 to -0.01), ECASS II (5.2% vs 4.4%, 95% CI = -0.03 to 0.01), and NINDS (7.7% vs 6.6%, 95% CI = -0.03 to 0.01) definitions. No differences in the 3-month mortality (17.9% vs 16.6%, 95% CI = -0.05 to 0.02), FFO (45.6% vs 46.0%, 95% CI = -0.04 to 0.05), FI (59.2% vs 60.7%, 95% CI = -0.03 to 0.06), or distribution in 3-month mRS scores (2 [1-4] vs 2 [0-4], 95% CI = -0.29 to 0.09) were documented between the 2 groups. INTERPRETATION: Given that patients on dual antiplatelet pretreatment have similar SICH, 3-month mortality rates, and functional outcomes compared to patients with no antiplatelet pretreatment, dual antiplatelet pretreatment history should not be used as a reason to withhold IVT in otherwise eligible AIS patients. Ann Neurol 2018;83:89-97.
引用
- Tsivgoulis G, Katsanos AH, Mavridis D, et al. Intravenous Thrombolysis for Ischemic Stroke Patients on Dual Antiplatelets. Ann Neurol. 2018. PMID: 30048012. doi:10.1002/ana.25269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。